151 related articles for article (PubMed ID: 9041341)
1. Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study.
Wainwright RB; Bulkow LR; Parkinson AJ; Zanis C; McMahon BJ
J Infect Dis; 1997 Mar; 175(3):674-7. PubMed ID: 9041341
[TBL] [Abstract][Full Text] [Related]
2. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results.
Wainwright RB; McMahon BJ; Bulkow LR; Parkinson AJ; Harpster AP
Arch Intern Med; 1991 Aug; 151(8):1634-6. PubMed ID: 1831343
[TBL] [Abstract][Full Text] [Related]
3. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population.
Wainwright RB; McMahon BJ; Bulkow LR; Hall DB; Fitzgerald MA; Harpster AP; Hadler SC; Lanier AP; Heyward WL
JAMA; 1989 Apr; 261(16):2362-6. PubMed ID: 2523002
[TBL] [Abstract][Full Text] [Related]
4. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions.
Heyward WL; Bender TR; McMahon BJ; Hall DB; Francis DP; Lanier AP; Alward WL; Ahtone JL; Murphy BL; Maynard JE
Am J Epidemiol; 1985 Jun; 121(6):914-23. PubMed ID: 3160233
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B Virus Revaccination With Standard Versus Pre-S Vaccine in Previously Immunized Patients With Celiac Disease.
Heshin-Bekenstein M; Turner D; Shamir R; Bar-Meir M; Dagan R; Zevit N; Silbermintz A
J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):400-3. PubMed ID: 25988560
[TBL] [Abstract][Full Text] [Related]
6. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.
McMahon BJ; Bruden DL; Petersen KM; Bulkow LR; Parkinson AJ; Nainan O; Khristova M; Zanis C; Peters H; Margolis HS
Ann Intern Med; 2005 Mar; 142(5):333-41. PubMed ID: 15738452
[TBL] [Abstract][Full Text] [Related]
7. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
[TBL] [Abstract][Full Text] [Related]
8. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth.
Dentinger CM; McMahon BJ; Butler JC; Dunaway CE; Zanis CL; Bulkow LR; Bruden DL; Nainan OV; Khristova ML; Hennessy TW; Parkinson AJ
Pediatr Infect Dis J; 2005 Sep; 24(9):786-92. PubMed ID: 16148845
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China.
Wang ZZ; Gao YH; Lu W; Jin CD; Zeng Y; Yan L; Ding F; Li T; Liu XE; Zhuang H
Hum Vaccin Immunother; 2017 Apr; 13(4):909-915. PubMed ID: 27874311
[TBL] [Abstract][Full Text] [Related]
10. [Combined immunoprophylaxis induces changes in anti-hepatitis B surface protein titer in infants born to mothers with positivity for hepatitis B surface antigen].
Wang J; Feng YL; Liu MH; Bai Y; Feng DH; Yuan NX; Du DQ; Feng WH; Liu HL; Yang Y; Liu JF; He YL; Song HX; Liu Y; Zhao YR; Chen TY
Zhonghua Gan Zang Bing Za Zhi; 2013 Aug; 21(8):580-3. PubMed ID: 24119736
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of compulsory and booster doses of hepatitis B vaccine among children in Cairo, Egypt.
Salama I; Sami S; Saleh R; Mohsen A; Elserougy S; Emam H; Said Z
J Egypt Public Health Assoc; 2017 Jun; 92(2):77-85. PubMed ID: 30184404
[TBL] [Abstract][Full Text] [Related]
12. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination.
Zhao YL; Han BH; Zhang XJ; Pan LL; Zhou HS; Gao Z; Hao ZY; Wu ZW; Ma TL; Wang F; Li Q; Bi SL; Ma JC
BMC Infect Dis; 2019 May; 19(1):482. PubMed ID: 31146699
[TBL] [Abstract][Full Text] [Related]
13. Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults.
Pan HX; Zeng Y; Song XF; Zhang YJ; Xu K; Liang ZL; Zhu FC
Vaccine; 2014 Jun; 32(29):3706-12. PubMed ID: 24681228
[TBL] [Abstract][Full Text] [Related]
14. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
[TBL] [Abstract][Full Text] [Related]
15. Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults.
Gara N; Abdalla A; Rivera E; Zhao X; Werner JM; Liang TJ; Hoofnagle JH; Rehermann B; Ghany MG
Clin Infect Dis; 2015 Feb; 60(4):505-13. PubMed ID: 25389254
[TBL] [Abstract][Full Text] [Related]
16. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates.
Ding L; Zhang M; Wang Y; Zhou S; Kong W; Smego RA
Clin Infect Dis; 1993 Sep; 17(3):475-9. PubMed ID: 8218692
[TBL] [Abstract][Full Text] [Related]
17. A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.
Simons BC; Spradling PR; Bruden DJ; Zanis C; Case S; Choromanski TL; Apodaca M; Brogdon HD; Dwyer G; Snowball M; Negus S; Bruce MG; Morishima C; Knall C; McMahon BJ
J Infect Dis; 2016 Jul; 214(2):273-80. PubMed ID: 27056956
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
[TBL] [Abstract][Full Text] [Related]
19. Increases in levels of antibody to hepatitis B surface antigen in an immunized population.
Bulkow LR; Wainwright RB; McMahon BJ; Parkinson AJ
Clin Infect Dis; 1998 Apr; 26(4):933-7. PubMed ID: 9564478
[TBL] [Abstract][Full Text] [Related]
20. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children.
Yuen MF; Lim WL; Cheng CC; Lam SK; Lai CL
Hepatology; 1999 Mar; 29(3):924-7. PubMed ID: 10051499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
